BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%
Go back to BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 9.57 -0.25 (2.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.82 | 52 Week High | $10.98 | |||
| Open | $9.72 | 52 Week Low | $1.63 | |||
| Day High | $9.72 | P/E | N/A | |||
| Day Low | $9.46 | EPS | $-0.68 | |||
| Volume | 585,233 | |||||
